BRCA2-related cancer predisposition
MONDO:0700269Hereditary cancer predisposition due to variation(s) in the BRCA2 gene. Germline pathogenic or likely pathogenic variants in the BRCA2 gene confer an autosomal dominant predisposition to hereditary breast and ovarian cancer. Tumor formation at other sites, including pancreatic and prostate cancer, have been described.
70 clinical trials for this condition and its sub-types, 36 tagged with BRCA2-related cancer predisposition itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of BRCA2-related cancer predisposition
-
Glioma susceptibility 3 0 trials
-
Can a Chemo-Targeted drug combo outsmart Treatment-Resistant prostate cancer?
Disease control Stopped earlyThis phase 2 trial is testing whether giving two chemotherapy drugs (docetaxel and carboplatin) followed by a maintenance drug called rucaparib can help men with metastatic castration-resistant prostate cancer that has specific DNA repair defects. The idea is that the chemo shrin…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Cancer drug niraparib tested before prostate surgery – early trial stopped
Disease control Stopped earlyThis phase II trial tested the drug niraparib (Zejula) in 11 men with high-risk prostate cancer that had not spread. All men had specific DNA repair gene mutations. They took niraparib before having their prostate removed surgically. The goal was to see if the drug could eliminat…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New test may expand olaparib benefits to more ovarian cancer patients
Knowledge-focused Stopped earlyThis study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatmen…
Phase 2 • Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC